A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma
The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-dir...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
11 May 2010
|
| In: |
BMC cancer
Year: 2010, Volume: 10, Pages: 1-8 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/1471-2407-10-190 |
| Online Access: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.1186/1471-2407-10-190 Verlag, kostenfrei, Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-10-190 
|
| Author Notes: | Andreas A. Schnitzbauer, Carl Zuelke, Christian Graeb, Justine Rochon, Itxarone Bilbao, Patrizia Burra, Koert P. de Jong, Christophe Duvoux, Norman M. Kneteman, Rene Adam, Wolf O. Bechstein, Thomas Becker, Susanne Beckebaum, Olivier Chazouillères, Umberto Cillo, Michele Colledan, Fred Fändrich, Jean Gugenheim, Johann P. Hauss, Michael Heise, Ernest Hidalgo, Neville Jamieson, Alfred Königsrainer, Philipp E. Lamby, Jan P. Lerut, Heikki Mäkisalo, Raimund Margreiter, Vincenzo Mazzaferro, Ingrid Mutzbauer, Gerd Otto, Georges-Philippe Pageaux, Antonio D. Pinna, Jacques Pirenne, Magnus Rizell, Giorgio Rossi, Lionel Rostaing, Andre Roy, Victor Sanchez Turrion, Jan Schmidt, Roberto I. Troisi, Bart van Hoek, Umberto Valente, Philippe Wolf, Heiner Wolters, Darius F. Mirza, Tim Scholz, Rudolf Steininger, Gunnar Soderdahl, Simone I. Strasser, Karl-Walter Jauch, Peter Neuhaus, Hans J. Schlitt and Edward K. Geissler |
| Summary: | The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibitor sirolimus can improve hepatocellular carcinoma (HCC)-free patient survival in liver transplant (LT) recipients with a pre-transplant diagnosis of HCC. |
|---|---|
| Item Description: | Gesehen am 27.06.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/1471-2407-10-190 |